Edwards Lifesciences Co. (NYSE:EW) Shares Bought by National Bank of Canada FI

National Bank of Canada FI increased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 214,861 shares of the medical research company's stock after purchasing an additional 9,352 shares during the period. National Bank of Canada FI's holdings in Edwards Lifesciences were worth $16,234,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $34,000. Operose Advisors LLC raised its position in shares of Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock worth $44,000 after acquiring an additional 452 shares during the last quarter. SRS Capital Advisors Inc. lifted its stake in shares of Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company's stock valued at $44,000 after acquiring an additional 474 shares during the period. NBC Securities Inc. acquired a new stake in Edwards Lifesciences in the third quarter worth about $52,000. Finally, ORG Partners LLC bought a new stake in Edwards Lifesciences during the 3rd quarter worth about $66,000. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the subject of several analyst reports. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an "in-line" rating for the company in a research report on Friday, April 26th. StockNews.com upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Monday, April 29th. OTR Global upgraded shares of Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research report on Tuesday, March 26th. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an "overweight" rating in a research note on Friday, April 26th. Finally, Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a "buy" rating in a research report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $93.27.

Edwards Lifesciences Stock Down 0.9 %

Shares of Edwards Lifesciences stock traded down $0.75 on Wednesday, reaching $85.09. 1,718,830 shares of the company were exchanged, compared to its average volume of 3,712,919. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average of $90.05 and a 200 day moving average of $79.69. The company has a market capitalization of $51.28 billion, a price-to-earnings ratio of 37.00, a PEG ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analysts' expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares of the company's stock, valued at approximately $3,390,542.49. The disclosure for this sale can be found here. Insiders sold a total of 237,749 shares of company stock valued at $20,920,934 over the last ninety days. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.